Once-daily oral ritlecitinib or brepocitinib versus placebo in patients with moderate-to-severely active Crohn's disease (PIZZICATO): an international, randomised, phase 2a trial
每日一次口服利特西替尼或布雷泊西替尼与安慰剂治疗中重度活动性克罗恩病患者的疗效比较(PIZZICATO):一项国际性、随机、2a期试验
期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2026.103820
Vermeire, Severine; Allegretti, Jessica R; Kim, Hyo Jong; Long, Millie D; Leszczyszyn, Jaroslaw; Schreiber, Stefan; Kierkus, Jaroslaw; Chandler, Paulette D; Ramakrishna, Jyoti; Peeva, Elena; Vincent, Michael S; Shojaee, Negin; Mahling, Ping; Banfield, Christopher; Banerjee, Anindita; Gale, Jeremy D; Hung, Kenneth E